Zhang Li-ping, Yu Feng, Jin Bao-fang, Wang Ye, Xu Hui-lin, DU Yan
Expanded Program on Immunization, Minhang District Center for Disease Control and Prevention, Shanghai 201101, China.
Zhonghua Er Ke Za Zhi. 2012 Nov;50(11):859-64.
To analyze the adverse events following immunization (AEFI) in Minhang District of Shanghai from 2007 to 2010 and evaluate the safety of vaccines.
The data of AEFI cases were collected and reported by the Vaccine Adverse Events Surveillance System (VAESS). The data were classified as non-serious or serious reaction according to the symptoms and medical records.
From 2007 to 2010, 5088 AEFI cases were reported to the surveillance system after 4.85 million doses of 24 kinds of vaccines (viral vaccines, bacterial vaccine and non-vaccine product) use. A total of 5013 non-serious AEFI were reported with a rate of 103.24/100 000 doses. Among the non-serious AEFIs, the majority were fever (3314 cases, 68.25/100 000 doses), followed by local reactions (1686 cases, 34.72/100 000 doses). A total of 75 serious AEFIs were reported, with a rate of 1.54/100 000 doses. The anaphylaxis (26 cases, 0.54/100 000 doses) accounted for the most among the serious AEFIs, followed by allergic rash (24 cases, 0.49/100 000 doses) and abscess at injection site (14 cases, 0.29/100 000 doses). The susceptibility of data on AEFI rose year by year from 2007 to 2010, and the reported rate rose from 40.48/100 000 in 2007 to 134.17/100 000 in 2010.
To maintain the sensitivity of AEFI surveillance is key to detect rare serious adverse events. The sensitivity should be enhanced, at the same time, pediatricians should treat the AEFI with standard methods, so as to minimize the negative impacts of vaccination and to maintain the confidence among the public.
分析2007年至2010年上海市闵行区预防接种异常反应(AEFI)情况,评价疫苗安全性。
通过预防接种异常反应监测系统(VAESS)收集并报告AEFI病例资料,依据症状及病历资料将数据分为一般反应和异常反应。
2007年至2010年,在使用485万剂24种疫苗(病毒疫苗、细菌疫苗及非疫苗类产品)后,监测系统共报告5088例AEFI。共报告5013例一般反应,报告发生率为103.24/10万剂。一般反应中,以发热为主(3314例,68.25/10万剂),其次为局部反应(1686例,34.72/10万剂)。共报告75例异常反应,报告发生率为1.54/10万剂。异常反应中,以过敏性休克为主(26例,0.54/10万剂),其次为过敏性皮疹(24例,0.49/10万剂)和接种部位脓肿(14例,0.29/10万剂)。2007年至2010年,AEFI数据敏感性逐年上升,报告发生率从2007年的40.48/10万升至2010年的134.17/10万。
保持AEFI监测敏感性是发现罕见严重不良反应的关键,应提高监测敏感性,同时儿科医生应规范处理AEFI,以减少预防接种的负面影响,维护公众信心。